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BACKGROUND: The potential prognostic value of several commonly investigated immunohistochemical markers in resected pancreatic
cancer is variably reported. The objective of this study was to conduct a systematic review of literature evaluating p53, p16, smad4,
bcl-2, bax, vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) expression as prognostic factors
in resected pancreatic adenocarcinoma and to conduct a subsequent meta-analysis to quantify the overall prognostic effect.
METHODS: Relevant literature was identified using Medline, EMBASE and ISI Web of Science. The primary end point was overall
survival assessed on univariate analysis. Only studies analysing resected pancreatic adenocarcinoma were eligible for inclusion and the
summary loge hazard ratio (logHR) and variance were pooled using an inverse variance approach. Evidence of heterogeneity was
evaluated using the w
2 test for heterogeneity and its impact on the meta-analysis was assessed by the I
2 statisic. Hazard ratios greater
than one reflect adverse survival associated with positive immunostaining.
RESULTS: Vascular endothelial growth factor emerged as the most potentially informative prognostic marker (11 eligible studies,
n¼767, HR¼1.51 (95% confidence interval, CI¼1.18–1.92)) with no evidence of any significant publication bias (Egger’s
test, P¼0.269). Bcl-2 (5 eligible studies, n¼314, HR¼0.51 (95% CI¼0.38–0.68)), bax (5 studies, n¼274, HR¼0.63
(95% CI¼0.48–0.83)) and p16 (3 studies, n¼229, HR¼0.63 (95% CI¼0.43–0.92)) also returned significant overall survival
differences, but in smaller patient series due to a lack of evaluable literature. Neither p53 (17 studies, n¼925, HR¼1.22
(95% CI¼0.96–1.56)), smad4 (5 studies, n¼540, HR¼0.88 (95% CI¼0.61–1.27)) nor EGFR (4 studies, n¼250, HR¼1.35
(95% CI¼0.80–2.27)) was found to represent significant prognostic factors when analysing the pooled patient data. There was
evidence of significant heterogeneity in four of the seven study groups.
CONCLUSION: These results support the case for immunohistochemical expression of VEGF representing a significant and reproducible
marker of adverse prognosis in resected pancreatic cancer.
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Pancreatic ductal adenocarcinoma is characterised by its singularly
aggressive tumour biology and unfavourable patient outcomes.
Despite overall 5-year survival rates of o5%, previous randomised
trials have demonstrated that for patients presenting with localised
disease, resection with administration of adjuvant chemotherapy is
associated with 5-year survival rates of over 20% (Neoptolemos
et al, 2004; Oettle et al, 2007).
Reliable identification of molecular prognostic markers is
important in order to facilitate the rational selection of potential
therapeutic targets in the development of novel cancer therapies
and to allow meaningful and reproducible risk stratification as part
of clinical trials. There is marked disparity in the literature
between individual studies as to the relative prognostic impact of
several immunohistochemical tissue markers in pancreatic cancer.
This may, in part, be explained by heterogeneity in patient
selection due to inclusion of resected and unresected patients
in survival analyses or inclusion of mixed tumour types and
laboratory methodology when comparing different studies.
The objective of the present study was to conduct a systematic
review and meta-analysis of published literature investigating the
commonly reported immunohistochemical prognostic markers in
resected primary tumour material from patients with pancreatic
adenocarcinoma and to identify potential sources of heterogeneity
when comparing the results of individual studies.
MATERIALS AND METHODS
Search strategy
Medline, EMBASE and ISI Web of Science were searched to
identify potentially relevant published literature. No chronological
search criteria were applied. Existing systematic reviews and
reference lists were also checked for any potentially relevant
Received 10 December 2010; revised 2 March 2011; accepted 8 March
2011; published online 29 March 2011
*Correspondence: Dr P Ghaneh; E-mail: p.ghaneh@liverpool.ac.uk
2Current address: North West Hub for Trial Methodology Research,
Centre for Medical Statistics and Health Evaluation, University of
Liverpool, Liverpool, UK
British Journal of Cancer (2011) 104, 1440–1451
& 2011 Cancer Research UK All rights reserved 0007– 0920/11
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sadditional studies. The most widely investigated and biologically
relevant immunohistochemical tissue markers for pancreatic
cancer were selected for meta-analysis. These comprised p53,
smad4, p16, bcl-2, bax, vascular endothelial growth factor (VEGF)
and epidermal growth factor receptor (EGFR).
Selection criteria
The following criteria were used to search English language articles
and abstracts: ‘(marker)’ AND (‘pancreas’ OR ‘pancreatic’) AND
(‘survival’ OR ‘prognosis’ OR ‘prognostic’). Each search was
repeated for individual markers by substituting the name
of marker of interest along with relevant synonyms: ‘p53’ OR
‘TP53’; ‘p16’ OR ‘p16*’ OR ‘CDKN2A’; ‘smad4’ OR ‘smad-4’ OR
‘smad*’; ‘DPC4’ OR ‘DPC-4’ OR ‘DPC*’; ‘bcl-2’ OR ‘bcl2’ OR ‘bcl’
OR ‘bcl*’; ‘bax’; ‘vascular endothelial growth factor’ OR ‘VEGF’
OR ‘VEGF*’; ‘epidermal growth factor receptor’ OR ‘EGFR’ OR
‘c-erbB*’ OR ‘erbB*’ OR ‘HER*’. The search was performed in
November 2009. Abstracts were initially checked for relevance and
the full article was retrieved for all potentially eligible studies.
Where part or all of the same patient series was included in more
than one publication, only the more recent or most complete study
was included in the analysis in order to avoid duplication of the
same survival data.
The following inclusion criteria were used to select literature:
only cases of resected pancreatic adenocarcinoma analysed,
immunohistochemical expression assessed in resected primary
tumour material, dichotomised univariate survival analysis
reported (i.e. positive vs negative staining) and overall survival
times used in analysis. For the analysis of VEGF, only studies
investigating the prognostic value of VEGF-A expression were
included. Authors were contacted for unpublished results in cases
where insufficient survival data were reported to estimate the loge
hazard ratio (logHR) and variance. Due to the minority of studies
reporting multivariable analyses, no attempt was made to use
any adjusted survival data as part of this meta-analysis (i.e. only
univariate survival data were extracted).
End points
The primary outcome measure was overall survival (i.e. date of
resection to date of death). Additional details were also collected in
order to identify potential sources of heterogeneity. These included
the specific primary antibody (and dilution) used for immuno-
histochemistry, the scoring criteria used to define positive staining
and relevant clinico-pathological data. An assessment of study
methodology was made according to previously defined criteria
(Hayden et al, 2006; McShane et al, 2006). These principles were
used to define 20 individual study characteristics, which were
deemed to be key factors to report in an immunohistochemical
prognostic study (Table 1). For any criterion not fulfilled
according to the information outlined in the article, one point
was deducted from a maximum of 20 and the final score
was recorded as a percentage. The eligibility criteria and quality
scoring were assessed by two independent investigators. Any
disagreement was resolved by discussion.
Statistical analysis
Previously reported indirect methods were utilised for extracting
the logHR and variance due to the paucity of prognostic literature,
which report these values directly (Parmar et al, 1998; Williamson
et al, 2002; Tierney et al, 2007). These values were either calculated
from the HR and 95% confidence interval (CI) where quoted, the
log rank P-value, or from the Kaplan–Meier survival curves
directly. The software used for these indirect calculations
was designed by Matthew Sydes and Jayne Tierney of the
Medical Research Council Clinical Trials Unit, London, UK
(Tierney et al, 2007). The logHR and variance for individual
studies were entered into RevMan 4.2 (Cochrane collaboration,
Oxford, UK) and pooled using a random effects inverse variance
approach. The overall prognostic effect of positive immunostain-
ing was recorded as an HR and 95% CI (i.e. an HR41 reflecting
adverse survival associated with positive immunostaining).
Heterogeneity was assessed using a w
2 test for heterogeneity with
a P-value of o0.10 taken to reflect the presence of significant
heterogeneity. The I
2 statistic was calculated to quantify the degree
of heterogeneity (Higgins and Thompson, 2002). A P-value of
o0.050 was taken to reflect significance for all other analyses.
Publication bias was assessed by inspection of the funnel plot with
Egger’s regression. Continuous data were compared using Spear-
man’s rank correlation and two-sided Mann–Whitney testing
for categorical data.
RESULTS
VEGF
The initial search returned a total of 255 studies. Following review
of these abstracts, 20 potentially relevant studies were identified as
eligible of which nine were excluded for the following reasons:
duplicated series of patients (Ikeda et al, 1999; Niedergethmann
et al, 2000; Tang et al, 2001), only VEGF-C and/or VEGF-D
analysed (Kurahara et al, 2004; Zhang et al, 2007), no dichot-
omised univariate survival analysis reported (Ellis et al, 1998;
Fujioka et al, 2001), mix of resected and unresected cases included
in survival analysis (Chung et al, 2006) and only VEGF receptor
status analysed (Bu ¨chler et al, 2002).
The 11 eligible studies (all retrospective) included a total
of 767 patients with a median number of 62 patients per
study (range¼19–142). Table 2 outlines the demographic,
Table 1 Methodological scoring criteria used
Study group
Study population adequately described
Gender/age 1 Point
Histology 1 Point
Period of recruitment 1 Point
Inclusion/exclusion criteria used 1 Point
Study attrition
490% of cases identified included in final analysis 1 Point
Reasons for attrition/loss to follow-up given 1 Point
Peri-operative mortality details 1 Point
Scientific methodology
IHC methodology outlined
Details of 11/21 Abs used 1 Point
Concentration of 11 Abs used 1 Point
Positive/negative controls outlined 1 Point
Description of scoring technique
41 independent scorer 1 Point
Scorers blinded to clinical data 1 Point
Criteria for positivity clearly outlined
Distribution (cytoplasm vs membranous vs nuclear) 1 Point
% positive cells for immunostaining classification 1 Point
Confounding factors considered
Adjuvant therapy details provided 1 Point
Histological breakdown according to IHC staining 1 Point
Statistical analysis
HR (confidence interval) provided 1 Point
Exact P-value quoted 1 Point
Numbers at risk for Kaplan–Meier curves 1 Point
Number of censored cases recorded 1 Point
Abbreviations: HR¼hazard ratio; IHC¼immunohistochemical.
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of these studies. The median quality score was recorded as 70%
(range¼60–95%). There was no significant difference in median
quality scores between significant and non-significant studies
(Mann–Whitney, P¼0.516). Similarly, there was no significant
correlation between study size and quality scores (Spearman’s
r¼0.139, P¼0.698). Figure 1 illustrates the Forrest plot for the
survival data. Significant heterogeneity was demonstrated accord-
ing to Cochran’s w
2 test (w
2¼22.08, P¼0.01; I
2¼54.7%). The
combined HR was recorded as 1.51 (95% CI¼1.18–1.92),
indicating that positive immunostaining for VEGF was signifi-
cantly associated with adverse survival in the pooled patient group.
When assessing the funnel plot for this analysis (Figure 2), the data
points approximated a symmetrical distribution (Egger’s test,
P¼0.269), indicating that publication bias is unlikely to be a
significant confounding factor in describing this relationship.
The median proportion of patients classified as VEGF positive in
the included studies was recorded as 60% (range¼32–71%). The
proportion of VEGF positive cases reported in each study failed to
exhibit any correlation with the assessment of methodological
quality (Spearman’s P¼0.491) or the % cutoff used to define
positive immunostaining (Spearman’s P¼0.388). Only six studies
reported the proportion of patients who received any form of
adjuvant therapy (Table 2) and administered treatment modalities
included a mix of both chemotherapy and chemoradiation. No
studies reported use of any neoadjuvant therapy and only a single
study reported use of intra-operative radiotherapy (Ikeda et al,
2001). Of the five studies that reported positive VEGF expression
as a significant adverse prognostic variable, only three conducted
some form of multivariate analysis. These three analyses included
a variety of disparate covariates alongside VEGF. However, each
reported that VEGF expression retained statistical significance.
bcl-2
The initial search returned a total of 232 abstracts of which 16
potentially eligible articles were retrieved. A total of 11 were
excluded for the following reasons: duplicated series of patients
(Nio et al, 2001a), mix of resected and unresected cases included
(Gansauge et al, 1998; Ma ¨kinen et al, 1998; Ohshio et al, 1998; Hu
et al, 1999), inclusion of ampullary tumours (Sinicrope et al, 1996),
no dichotomised univariate survival analysis conducted (Evans
et al, 2001; Stipa et al, 2002; Sun et al, 2002) and insufficient
survival data reported for indirect estimation of logHR and
variance (Friess et al, 1998; Campani et al, 2001).
The five eligible studies included a total of 314 patients with a
median number of 63 patients per study (range¼52–70) (Table 2).
The median quality score was recorded as 75% (range¼65–85%)
and the median proportion of bcl-2 positive cases was 33%
(range¼12–67%). Figure 2 illustrates the Forrest plot for the
pooled survival data. There was no evidence of any significant
heterogeneity (w
2¼1.19, P¼0.88). The combined HR was
recorded as 0.51 (95% CI¼0.38–0.68), indicating a significant
association between positive bcl-2 immunostaining and more
favourable survival in the pooled patient group. Despite the limited
number of studies included, the funnel plot for this analysis
failed to demonstrate any obvious asymmetry (Figure 3). Three
studies reported use of either adjuvant chemotherapy or chemor-
adiation and a single study (Bold et al, 1999) also reported use
of neoadjuvant chemoradiation in 43 out of the 70 patients
analysed. Of the two studies rejected due to incomplete
survival data (Friess et al, 1998; Campani et al, 2001), both failed
to observe any significant prognostic effect associated with
bcl-2 expression. Neither study reported the direction of the
prognostic effect.
Table 2 Methodological and clinico-pathological data for eligible prognostic studies evaluating VEGF, bcl-2, bax and p16
Reference n
HR
(95% CI)
Signi-
ficant
11 Ab
(+dilution)
IHC
+ve
IHC
cutoff (%) Male Age N1 T3/T4 Well Mod. Poor
Adjuvant
therapy
VEGF
Itakura et al (1997) 75 1.12 (0.69–1.82) No NC (30mgml
–1) 48 (64) 410 46 (61) 62 47 (63) 43 (57) 13 (17) 44 (59) 18 (24) NS
Fujimoto et al (1998) 50 0.78 (0.44–1.40) No Santa Cruz A20 (1:200) 28 (40) NS 28 (56) 62 29 (58) 34 (68) 9 (18) 31 (62) 10 (20) NS
Seo et al (2000) 142 1.46 (1.02–2.09) Yes Santa Cruz (NS) 94 (66) 430 79 (56) 64 95 (67) NS NS NS NS NS
Ikeda et al (2001) 48 2.74 (1.44–5.20) Yes Santa Cruz (1:200) 31 (65) 410 37 (77) 64 24 (50) 40 (83) 15 (31) 28 (58) 5 (11) 48 (100)
Knoll et al (2001) 19 2.37 (0.88–6.40) No R&D Ab293NA (1:200) 13 (68) 45 11 (58) 58 18 (95) 1 (5) 1 (5) 12 (63) 6 (32) 0 (0)
Niedergethmann et al
(2002)
70 2.48 (1.22–5.05) Yes Santa Cruz (1:200) 28 (40) 410 42 (60) 63 41 (59) NS 25 (36) 45 (64) 22 (31)
Kuwahara et al (2003) 55 2.08 (1.12–3.88) Yes Santa Cruz sc152 (1:200) 39 (71) 450 34 (62) 64 30 (55) 40 (73) 13 (24) 33 (60) 9 (16) NS
Lim et al (2004) 72 0.82 (0.49–1.37) No Santa Cruz (1:2000) 23 (32) 410 43 (60) 60 38 (53) 59 (82) 14 (19) 44 (61) 14 (19) 26 (36)
Khorana et al (2005) 124 1.30 (0.87–1.95) No Zymed (1:50) 70 (56) 45 69 (56) 67 56 (45) 69 (58) 23 (19) 52 (43) 45 (38) 88 (79)
Tang et al (2006) 50 1.46 (0.84–2.54) No NS (2mgml
–1) 25 (50) 410 25 (50) 63 39 (78) 25 (50) 15 (30) 31 (62) 4 (8) NS
Ai et al (2008) 62 2.34 (1.41–3.89) Yes Neomarkers (NS) 37 (60) 410 36 (58) 65 49 (79) 32 (52) 17 (27) 15 (24) 30 (48) 0 (0)
bcl-2
Bold et al (1999) 70 0.64 (0.35–1.18) No DAKO (NS) 23 (33) 425% 36 (51) 64 32 (46) NS 15 (22) 37 (55) 15 (22) 19 (27)
Nio et al (2001b) 66 0.45 (0.25–0.82) Yes DAKO M0887 (1:100) 16 (24) 45% 31 (47) 66 54 (82) NS 33 (50) 29 (44) 4 (6) 36 (55)
Magistrelli et al (2006) 67 0.56 (0.33–0.96) Yes DAKO c124 (1:40) 45 (67) 45% 45 (67) 63 34 (51) 40 (62) 14 (21) 28 (42) 15 (22) 30 (45)
Sarela et al (2002) 52 0.50 (0.08–3.33) No DAKO (1:40) 6 (12) 410% 27 (52) 64 40 (78) 49 (94) 11 (22) 24 (47) 16 (31) NS
Dong et al (2005b) 59 0.43 (0.25–0.74) Yes DAKO M124(1:100) 21 (36) 45% 19 (32) 55 54 (82) NS 19 (32) 21 (36) 19 (32) NS
bax
Friess et al (1998) 60 0.47 (0.23–0.97) Yes Santa Cruz (NS) 50 (83) NS 32 (53) 63 38 (63) NS NS NS NS NS
Evans et al (2001) 23 0.80 (0.28–2.29) No Santa Cruz (1:1600) 6 (26) 45% 15 (65) 59 38 (63) NS 5 (22) 13 (54) 5 (22) 0 (0)
Nio et al (2001b) 65 0.49 (0.28–0.85) Yes DAKO A3533 (1:100) 42 (65) 410% 31 (47) 66 54 (82) NS 33 (50) 29 (44) 4 (6) 36 (55)
Magistrelli et al (2006) 67 0.56 (0.33–0.95) Yes Zymed c2D2 (1:80) 36 (54) 410% 45 (67) 63 34 (51) 40 (62) 14 (21) 28 (42) 15 (22) 30 (45)
Dong et al (2005b) 59 0.93 (0.57–1.52) No DAKO A3533 (1:100) 29 (49) 410% 19 (32) 55 54 (82) NS 19 (32) 21 (36) 19 (32) NS
p16
Naka et al (1998) 32 0.45 (0.21–0.96) Yes Santa Cruz C20 (1:500) 19 (59) NS 20 (63) 65 23 (72) 13 (41) NS NS NS NS
Kawesha et al (2000) 157 0.82 (0.50–1.33) No Santa Cruz (1:100) 21 (13) 45% 100 (64) 60 71 (46) NS 21 (13) 77 (49) 59 (38) 13 (8)
Gerdes et al (2002) 40 0.51 (0.25–1.04) No Pharmingen G175–405
(1:50)
13 (33) 45% 22 (55) NS 16 (40) NS NS NS NS 0 (0)
Abbreviations: CI¼confidence interval; HR¼hazard ratio; IHC¼immunohistochemical; NC¼non-commercial; NS¼not specified; VEGF¼vascular endothelial growth factor.
% in parentheses unless otherwise stated. IHC and/or clinico-pathological data were incompletely reported in some studies. Well/Mod/Poor refers to tumour differentiation.
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The initial search yielded 76 studies. Following review of the
abstracts, a total of seven potentially eligible articles were
identified. Two of these were excluded due to either a duplicated
patient series (Hashimoto et al, 2005) or the inclusion of
periampullary cancers of non-pancreatic origin in the survival
analysis (Tomazic et al, 2004). Three of the five eligible studies
investigated the prognostic effect of both bcl-2 and bax and were,
therefore, included in both meta-analyses (Magistrelli et al, 2006;
Nio et al, 2001b; Dong et al, 2005b).
The five eligible studies investigating bax included a total of 274
patients with a median number of 60 patients per study
(range¼23–67) (Table 2). The median quality score was 65%
(range¼55–85%) and the median proportion of bax positive cases
was 54% (range¼26–83%). Figure 2 illustrates the Forrest plot for
the pooled survival data. There was no evidence of any significant
heterogeneity (w
2¼4.25, P¼0.37; I
2¼5.9%). The combined HR
was recorded as 0.63 (95% CI¼0.48–0.83) and the funnel plot for
this analysis is shown in Figure 3.
p16
The initial search returned 91 studies, seven of which were
potentially relevant. Following review of these seven articles, three
fulfilled all of the eligibility criteria. The remaining studies were
rejected due to the inclusion of unresected cases (Hu et al, 1997;
Biankin et al, 2002), no IHC used in tissue analysis (Ohtsubo et al,
2003) or only disease-free survival times reported (Jeong et al,
2005). A total of 229 patients were included in the pooled analysis.
There was no evidence of any significant heterogeneity across the
three included studies (w
2¼2.23, P¼0.33; I
2¼10.5%). A com-
bined HR of 0.63 (95% CI¼0.43–0.92) was obtained, indicating a
significant association between p16 expression and more favour-
able survival.
p53
The initial search returned a total of 337 studies. Following review
of these abstracts, 58 potentially relevant studies were retrieved of
which 17 fulfilled all of the inclusion criteria. The remaining
Naka et al –0.7985 (0.3849) 23.25 0.45 [0.21, 0.96]
Gerdes et al –0.6733 (0.3611) 26.14 0.51 [0.25, 1.04]
Kawesha et al –0.1985 (0.2475) 50.61 0.82 [0.50, 1.33]
Total (95% CI) 100.00 0.63 [0.43, 0.92]
Test for heterogeneity: 2 = 2.23, df = 2 (P = 0.33), I2 = 10.5%
Test for overall effect: Z = 2.39 (P = 0.02)
0.1 0.2 0.5 1 2 5 10
Favours positive Favours negative
bcl-2
Dong et al –0.8440 (0.2766) 27.23 0.43 [0.25, 0.74]
Nio et al –0.7985 (0.3090) 21.82 0.45 [0.25, 0.82]
Sarela et al –0.6932 (0.9667) 2.23 0.50 [0.08, 3.33]
Magistrelli et al –0.5798 (0.2772) 27.11 0.56 [0.33, 0.96]
Bold et al –0.4463 (0.3105) 21.61 0.64 [0.35, 1.18]
Total (95% CI) 100.00 0.51 [0.38, 0.68]
Test for heterogeneity: 2 = 1.19, df = 4 (P = 0.88), I2 = 0%
Test for overall effect: Z = 4.66 (P < 0.00001)
bax
Friess et al –0.7550 (0.3722) 13.51 0.47 [0.23, 0.97]
Nio et al –0.7134 (0.2795) 23.95 0.49 [0.28, 0.85]
Magistrelli et al –0.5798 (0.2680) 26.05 0.56 [0.33, 0.95]
Evans et al –0.2231 (0.5361) 6.51 0.80 [0.28, 2.29]
Dong et al –0.0726 (0.2498) 29.98 0.93 [0.57, 1.52]
Total (95% CI) 100.00 0.63 [0.48, 0.83]
Test for heterogeneity: 2 = 4.25, df = 4 (P = 0.37), I2 = 5.9%
Test for overall effect: Z = 3.36 (P = 0.0008)
Fujimoto et al –0.2485 (0.2971) 8.74 0.78 [0.44, 1.40]
Lim et al –0.1985 (0.2620) 9.83 0.82 [0.49, 1.37]
Itakura et al 0.1133 (0.2483) 10.29 1.12 [0.69, 1.82]
Khorana et al 0.2624 (0.2065) 11.78 1.30 [0.87, 1.95]
Tang et al 0.3784 (0.2828) 9.17 1.46 [0.84, 2.54]
Seo et al 0.3784 (0.1830) 12.66 1.46 [1.02, 2.09]
Kuwahara et al 0.7324 (0.3178) 8.16 2.08 [1.12, 3.88]
Ai et al 0.8502 (0.2589) 9.94 2.34 [1.41, 3.89]
0.8629 (0.5070) 4.48 2.37 [0.88, 6.40]
Niedergethmann et  l 0.9083 (0.3627) 7.03 2.48 [1.22, 5.05]
Ikeda et al 1.0080 (0.3265) 7.92 2.74 [1.44, 5.20]
Total (95% CI) 100.00 1.51 [1.18, 1.92]
Test for heterogeneity: 2 = 22.08, df = 10 (P = 0.01), I2 = 54.7%
Test for overall effect: Z = 3.30 (P = 0.0010)
VEGF
p16
LogHR (SE) HR (95% CI) Weight (%) HR (95% CI)
Knoll et al
Figure 1 Forrest plot to assess overall effect of VEGF, bcl-2, bax and p16 expression on survival.
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patients (Dergham et al, 1997a; Dong et al, 1998b; Nio et al, 1998;
Nio et al, 1999; Dong et al, 2000; Linder et al, 2001; Nio et al,
2001a), no dichotomised univariate survival analysis conducted
(Sessa et al, 1998; Karademir et al, 2000; Evans et al, 2001; Fujioka
et al, 2001; Gazzaniga et al, 2001; Biankin et al, 2002; Dang et al,
2002; Hashimoto et al, 2005; Dong et al, 2007; Smeenk et al, 2007),
no IHC used in tissue analysis (Weyrer et al, 1996; Li et al, 1999;
Yamaguchi et al, 2000; Ohshio et al, 2002; Dong et al, 2003),
unresected cases included in survival analysis (Zhang et al, 1994;
Aizawa et al, 1996; Lundin et al, 1996; Coppola et al, 1998;
Dergham et al, 1998; Ma ¨kinen et al, 1998; Ohshio et al, 1998; Hu
et al, 1999; Takikita et al, 2009), mix of different tumour types
included (Sinicrope et al, 1996; Sato et al, 1997; Gansauge et al,
1998; Yu et al, 2004), only disease-free survival reported
(Jeong et al, 2005) and insufficient survival data reported
(Dergham et al, 1997b; Campani et al, 1999; Stipa et al, 2002;
Hermanova et al, 2009).
The 17 eligible studies included a total of 925 patients with a
median number of 48 patients per study (range¼26–157)
(Table 3). Nuclear staining of p53 was used for scoring in all
cases. Five studies (29%) reported a significant adverse association
between p53 expression and survival. The median quality
score was recorded as 65% (range¼45–90%) and the median
proportion of patients exhibiting positive p53 immunostaining was
47% (range¼25–68%). There was no significant association
between the IHC cutoff score used and the proportion of cases
classified as p53 positive (Spearman’s n ˜ ¼0.389, P¼0.206).
Furthermore, there was no significant difference in median
quality scores between significant and non-significant studies
(Mann–Whitney, P¼0.243).
Figure 2 illustrates the Forrest plot for the survival data. There
was no evidence of any significant publication bias (Egger’s test,
P¼0.298). Significant heterogeneity was demonstrated according
to Cochran’s w
2 test (w
2¼37.88, P¼0.002; I
2¼57.8%). The
combined HR was recorded as 1.22 (95% CI¼0.96–1.56),
indicating no significant overall association between p53 expres-
sion and survival. Of the four studies excluded due to incomplete
reporting of survival data, only one reported a significant
association between p53 expression and survival (Stipa et al, 2002).
smad4
The initial search returned 81 studies. Following review of these
abstracts, five potentially relevant studies were identified, which
were all found to be eligible for analysis. The combined number of
patients was 540 with a median of 88 patients per study
(range¼34–249) (Table 3). The median quality score was 75%
Sarela et al –0.6350 (0.7980) 1.96 0.53 [0.11, 2.53]
Bold et al –0.4780 (0.3021) 6.63 0.62 [0.34, 1.12]
Magistrelli et al –0.3857 (0.2725) 7.16 0.68 [0.40, 1.16]
Ahrendt et al –0.2614 (0.3457) 5.90 0.77 [0.39, 1.52]
Naka et al –0.1744 (0.4678) 4.26 0.84 [0.34, 2.10]
Kawesha et al –0.1054 (0.1726) 9.06 0.90 [0.64, 1.26]
Virkajarvi et al –0.0101 (0.3858) 5.30 0.99 [0.46, 2.11]
Yamasawa et al 0.0100 (0.2524) 7.53 1.01 [0.62, 1.66]
Dong et al 0.0198 (0.2709) 7.19 1.02 [0.60, 1.73]
Gerdes et al 0.1484 (0.3300) 6.15 1.16 [0.61, 2.21]
Lee et al 0.1570 (0.5077) 3.84 1.17 [0.43, 3.16]
Yokoyama et al 0.5596 (0.2782) 7.06 1.75 [1.01, 3.02]
Digiuseppe et al 0.5710 (0.3156) 6.40 1.77 [0.95, 3.29]
Bergan et al 0.7701 (0.3241) 6.25 2.16 [1.14, 4.08]
Linder et al 0.9969 (0.3324) 6.12 2.71 [1.41, 5.20]
Gansauge et al 1.0886 (0.4222) 4.80 2.97 [1.30, 6.79]
Jinfeng et al 1.1569 (0.4555) 4.40 3.18 [1.30, 7.77]
Total (95% CI) 100.00 1.22 [0.96, 1.56]
Test for heterogeneity: 2 = 37.88, df = 16 (P = 0.002), I2 = 57.8%
Test for overall effect: Z = 1.63 (P = 0.10)
Toga et al –0.6733 (0.3276) 17.20 0.51 [0.27, 0.97]
Tascilar et al –0.3011 (0.1438) 30.10 0.74 [0.56, 0.98]
Khorana et al –0.1278 (0.2015) 25.67 0.88 [0.59, 1.31]
Hua et al –0.0619 (0.4042) 13.47 0.94 [0.43, 2.08]
Biankin et al 0.8671 (0.4023) 13.55 2.38 [1.08, 5.24]
Total (95% CI) 100.00 0.88 [0.61, 1.27]
Test for heterogeneity: 2 = 9.86, df = 4 (P = 0.04), I2 = 59.4%
Test for overall effect: Z = 0.70 (P = 0.49)
p53
smad4
Bloomston et al –0.2357 (0.2682) 29.94 0.79 [0.47, 1.34]
Dong et al 0.0834 (0.3872) 22.47 1.09 [0.51, 2.32]
Smeenk et al 0.6575 (0.3804) 22.85 1.93 [0.92, 4.07]
Ueda et al 0.8109 (0.3482) 24.74 2.25 [1.14, 4.45]
Total (95% CI) 100.00 1.35 [0.80, 2.27]
Test for heterogeneity: 2 = 7.20, df = 3 (P = 0.07), I2 = 58.3%
Test for overall effect: Z = 1.13 (P = 0.26)
0.1 0.2 0.5 1 2 5 10
EGFR
LogHR (SE) HR (95% CI) HR (95% CI) Weight (%)
Favours positive Favours negative
Figure 2 Forrest plot to assess overall effect of p53, smad4 and EGFR expression on survival.
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s(range¼60–95%) and the median proportion of patients exhibit-
ing positive smad4 immunostaining was 45% (range¼15–76%).
Figure 2 illustrates the Forrest plot. There was evidence of
significant heterogeneity across the included studies (w
2¼9.86,
P¼0.04; I
2¼59.4%). A combined HR of 0.88 (95% CI¼0.61–
1.27) was recorded, indicating no significant overall association
between smad4 expression and survival in the pooled
patient group.
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Figure 3 Funnel plots to assess publication bias for VEGF, bcl-2, bax and p53 meta-analyses. Note: P-values for result of Egger’s regression to assess
publication bias.
Table 3 Methodological and clinico-pathological data for eligible prognostic studies evaluating p53, smad4 and EGFR
Reference n
HR
(95% CI)
Signi-
ficant 11 Ab (+ dilution)
IHC
+ve
IHC
cutoff
(%) Male Age N1 T3/T4 Well Mod. Poor
Adjuvant
therapy
p53
DiGiuseppe et al (1994) 48 1.77 (0.95–3.29) No Novocastra CM-1 (1:1000) 26 (54) NS 25 (52) 61 NS NS NS NS NS NS
Yokoyama et al (1994) 57 1.75 (1.01–3.02) Yes Novocastra DO7 (1:100) 33 (58) NS NS 64 25 (45) 27 (47) 37 (65) 20 (35) NS
Lee et al (1995) 26 1.17 (0.43–3.16) No Biogenex CM1 (NS) 7 (27) NS 14 (54) NS NS NS 2 (8) 20 (77) 4 (15) NS
Linder et al (1997) 48 2.71 (1.41–5.20) Yes DAKO DO7 (1:50) 22 (46) 41 36 (68) 66 18 (38) 26 (49) 5 (9) 18 (34) 30 (57) NS
Virkaja ¨rvi et al (1997) 36 0.99 (0.46–2.11) No Novocastra CM-1 (1:1000) 15 (42) 41 16 (44) 64 NS NS NS NS NS NS
Naka et al (1998) 32 0.84 (0.34–2.10) No Novocastra BP53-12 (1:50) 19 (59) NS 20 (63) 65 23 (72) 13 (41) NS NS NS NS
Bold et al (1999) 70 0.62 (0.34–1.12) No Oncogene DO1 (NS) 33 (47) 425 36 (51) 64 38 (54) NS 15 (22) 37 (56) 15 (22) 19 (27)
Gansauge et al (1999) 26 2.97 (1.30–6.79) Yes Oncogene DO1 (1:500) 11 (42) NS 12 (50) 59 22 (85) NS NS NS NS 26 (100)
Ahrendt et al (2000) 43 0.77 (0.39–1.52) No DAKO DO7 (1:2000) 26 (60) 433 24 (55) 63 23 (53) 22 (51) 11 (26) 23 (55) 8 (19) 29 (66)
Bergan et al (2000) 60 2.16 (1.14–4.08) Yes Novocastra DO7 (1:100) 15 (25) 45 41 (50) 62 18 (30) 21 (35) 25 (42) 23 (38) 12 (20) 0 (0)
Kawesha et al (2000) 157 0.90 (0.64–1.26) No DAKO DO7 (1:300) 64 (41) 45 100 (64) 60 71 (46) NS 21 (13) 77 (49) 59 (38) 13 (8)
Gerdes et al (2002) 40 1.16 (0.61–2.21) No DAKO DO7 (1:400) 13 (33) 410 22 (55) NS 16 (40) NS NS NS NS 0 (0)
Sarela et al (2002) 52 0.53 (0.11–2.53) No DAKO DO7 (1:100) 28 (54) 410 27 (52) 64 40 (78) 49 (94) 11 (22) 24 (47) 16 (31) NS
Yamasawa et al (2002) 72 1.01 (0.62–1.66) No Oncogene DO1 (2mg/ml) 34 (47) 420 34 (47) 65 21 (29) 42 (58) 35 (49) 32 (44) 5 (7) 41 (57)
Dong et al (2005a) 59 1.02 (0.60–1.73) No DAKO DO7 (1:20) 40 (68) 410 38 (64) NS 47 (80) NS 19 (32) 21 (36) 19 (32) NS
Magistrelli et al (2006) 67 0.68 (0.40–1.16) No DAKO DO7 (1:50) 32 (48) 45 45 (67) 63 34 (51) 40 (62) 14 (21) 28 (42) 15 (22) 30 (45)
Jinfeng et al (2007) 32 3.18 (1.30–7.77) Yes DAKO DO7 (1:50) 13 (41) 410 19 (59) 63 18 (56) 23 (72) 11 (34) 18 (56) 3 (10) NS
smad4
Tascilar et al (2001) 249 0.74 (0.56–0.98) Yes Santa Cruz B8 (1:100) 111 (46) NS 139 (56) 65 NS NS NS NS NS NS
Biankin et al (2002) 45 2.38 (1.08–5.24) Yes Santa Cruz B8 (NS) 10 (22) 45 27 (60) 61 21 (47) NS 5 (11) 28 (62) 12 (27) 8 (16)
Hua et al (2003) 34 0.94 (0.43–2.08) No Santa Cruz B8 (1:100) 26 (76) NS 22 (65) 55 14 (41) NS 27 (79) 7 (21) NS
Toga et al (2004) 88 0.51 (0.27–0.97) Yes Santa Cruz B8 (1:100) 13 (15) 410 43 (49) 66 78 (89) 33 (37) 37 (42) 45 (51) 6 (7) 58 (66)
Khorana et al (2005) 124 0.88 (0.59–1.31) No Santa Cruz (1:400) 59 (48) 45 69 (56) 67 56 (45) 69 (58) 23 (19) 52 (43) 45 (38) 88 (79)
EGFR
Dong et al (1998a) 57 1.09 (0.51–2.32) No Oncogene 985/996 (1:20) 39 (68) NS 20 (35) 55 46 (81) NS 18 (32) 22 (39) 17 (30) 7 (12)
Ueda et al (2004) 76 2.25 (1.14–4.45) Yes Zymed 31G7 (1:200) 47 (62) 410 57 (75) 63 59 (78) NS 11 (14) 32 (42) 33 (43) NS
Bloomston et al (2006) 71 0.79 (0.47–1.34) No Dakocytomation
218C9 (NS)
49 (69) 41 40 (56) 65 41 (58) 57 (81) 6 (9) 45 (63) 20 (28) NS
Smeenk et al (2007) 46 1.93 (0.92–4.07) No DAKO H11 (NS) 11 (24) 41 37 (66) 63 29 (52) 34 (61) 6 (11) 43 (77) 7 (12) 19 (34)
Abbreviations: CI¼confidence interval; EGFR¼epidermal growth factor receptor; HR¼hazard ratio; IHC¼immunohistochemical; NC¼non-commercial; NS¼not specified.
% in parentheses unless otherwise stated. IHC and/or clinico-pathological data were incompletely reported in some studies. Well/Mod./Poor refers to tumour differentiation.
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The initial search identified 324 studies. Following review of these
abstracts, 10 potentially relevant articles were retrieved. Six of
these studies were rejected for the following reasons: duplicated
series of patients (Uegaki et al, 1997; Ueda et al, 2006), no
dichotomised univariate survival analysis conducted (Yamanaka
et al, 1993; Zhang and Yuan, 2002) and unresected cases included
in analysis (Gansauge et al, 1998; Takikita et al, 2009). The four
eligible studies included a total of 250 patients (Table 3). Only a
single study reported a significant relationship between EGFR
expression and survival (Ueda et al, 2004). The median quality
score was 70% (range¼65–70%). Figure 2 illustrates the Forrest
plot for the pooled data. Significant heterogeneity was demon-
strated (w
2¼7.20, P¼0.07). The combined HR was recorded as
1.35 (95% CI¼0.80–2.27), indicating no significant overall
association between EGFR expression and survival.
DISCUSSION
Previous meta-analyses of studies investigating the prognostic
value of molecular markers have been published for different
malignancies. These include VEGF (Delmotte et al, 2002; Kyzas
et al, 2005a; Des Guetz et al, 2006), bcl-2 (Martin et al, 2003;
Callagy et al, 2008) and p53 (Kyzas et al, 2005b; Malats et al, 2005).
To date, no such meta-analysis has been undertaken for any
studies evaluating immunohistochemical prognostic markers in
resected pancreatic cancer.
Meta-analysis of prognostic literature is associated with a
number of inherent limitations. One of these key limitations is
the general prevalence of retrospective study design in this setting.
None of the studies included in the current meta-analysis specified
a prospective design and archived paraffin-embedded tumour
material was utilised for IHC in all cases. This indicates that
availability of tissue is invariably the main determinant of study
size rather than any specific considerations relating to adequate
statistical power in order to reliably detect a prognostic effect
for the marker of interest. The availability and adequacy of
corresponding clinico-pathological data is also a significant
consideration in retrospective studies of this type and we identified
several studies reporting incomplete datasets with regard to
histopathological details. Alongside this, an additional hindrance
to meta-analysis of prognostic literature is the general lack of
multivariable survival data. This is usually attributable to the fact
that the number of patients included in each study is typically
small, precluding any meaningful attempt at analysing multiple
covariates.
Additional challenges in the interpretation and comparison of
immunohistochemical prognostic studies include variability in
patient selection (i.e. resected and unresected cases, inclusion of
non-pancreatic periampullary tumours), disparate immunohisto-
chemical criteria used for prognostic classification, bias associated
with the statistical approach to analysis of survival data
(e.g. selection of data-driven cutoff values for continuous
variables), incomplete reporting of survival data, duplicated
patient series and publication bias arising as a result of selective
reporting of ‘positive’ studies (Altman, 2001). In order to
overcome some of these comparative difficulties, specific inclusion
criteria were applied in order to select studies for meta-analysis.
Only studies including resected pancreatic adenocarcinoma were
included in order to avoid any confounding effects on survival
associated with differing proportions of resected and unresected
cases. Any studies including periampullary tumours of non-
pancreatic origin were also excluded due to the disparity in
survival outcomes characteristically associated with ampullary,
duodenal and bile duct adenocarcinomas when compared with
pancreatic adenocarcinoma (Riall et al, 2006). Furthermore,
in cases where part or all of the same patient series was included
in more than one publication, only the more recent or most
complete study was included in the analysis in order to avoid
duplicating the same patient data for the immunohistochemical
marker of interest. For those studies where insufficient survival
data was reported to generate indirect calculations for the logHR
and variance, authors were contacted for additional survival data.
However, in all cases the authors were either unable to provide
any supplementary data or no response was received. The only
supplementary raw data obtained was for two studies previously
conducted at our own institution (Kawesha et al, 2000; Evans et al,
2001). Therefore, no subsequent attempt to request individual
patient survival data for all eligible studies was undertaken,
although this would have been potentially beneficial.
When analysing the overall relationships between individual
study size, reported prognostic significance and methodological
quality scores in the present study, there was a significant trend
towards superior methodological quality in larger studies as one
might reasonably expect, despite the fact that study size itself was
not one of the criteria used for quality scoring. When considering
the overall effect of potential publication bias in this analysis, only
a minority of studies (21 out of 50) actually reported a statistically
significant prognostic result. Furthermore, the funnel plots and
Egger’s tests for the individual analyses, although more difficult to
interpret when fewer studies were included, were not generally
indicative of any strong publication bias.
Vascular endothelial growth factor emerged as the most
potentially informative immunohistochemical prognostic marker
from the pooled data. Vascular endothelial growth factor com-
prises four ligands (VEGF-A, VEGF-B, VEGF-C and VEGF-D),
which exhibit specific binding profiles with three transmembrane
VEGF receptors (VEGF-I, -II and -III) and promote intracellular
tyrosine kinase cascades when activated. The VEGF-A (usually
referred to simply as VEGF) mediates the key pro-angiogenic
properties of proliferation and migration of endothelial cells along
with increasing vascular permeability (Yamazaki and Morita, 2006;
Dallas et al, 2007). Alternate gene splicing results in a number of
VEGF-A isoforms of differing amino-acid lengths, the smaller of
which (e.g. 121 and 165) are secreted while the larger (e.g. 189 and
206) remains cell associated. VEGF-C and VEGF-D are implicated
in the process of lymphangiogenesis (Achen and Stacker, 2008)
while the function of VEGF-B is incompletely understood (Nash
et al, 2006). Pancreatic cancer cells have been demonstrated to
express both VEGF ligand and its receptors, implicating a potential
VEGF-mediated autocrine loop in the proliferation of pancreatic
malignancy (Bu ¨chler et al, 2002).
The results from the present study demonstrate that, despite
variability between eligible studies as to the relative prognostic
impact of VEGF expression in resected pancreatic adenocarcino-
ma, the observed survival trend is concordant with that reported
for other malignancies in similar meta-analyses (Delmotte et al,
2002; Kyzas et al, 2005a,b; Des Guetz et al, 2006). When comparing
the value for the pooled HR identified in the present study (1.51
(95% CI¼1.18–1.92)) with the above referenced studies, the order
of magnitude for this effect is also broadly comparable for that
quoted for both lung cancer (1.48 (95% CI¼1.27–1.72)) and
colorectal cancer (1.65 (95% CI¼1.27–2.14)).
Significant heterogeneity was observed when analysing
the logHR estimates from the eligible studies. Evaluation of the
relevant methodological and clinico-pathological characteristics of
each study revealed a number of potential sources of heterogeneity
in study methodology. Nine studies reported use of commercially
available anti-VEGF primary antibodies, all of which exhibit
broadly comparable binding characteristics with the common
splice variants of VEGF-A. When analysing the concentrations of
primary antibody utilised, most studies reported comparable
dilution ratios. However, the concentration was not specified
in two studies. This issue is potentially relevant for the
study reporting use of the lowest primary antibody dilution
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s(Lim et al, 2004) as this was one of only two studies, which
indicated a contradictory prognostic effect when compared with
the overall group (i.e. a non-significant trend towards adverse
survival with negative VEGF immunostaining).
When reviewing the immunohistochemical criteria used for
VEGF scoring, the majority of studies reported a scoring system
based on cytoplasmic staining of tumour cells. Where the
distribution of immunostaining used for scoring was not explicitly
stated in the text (i.e. cytoplasmic, membranous, nuclear, stromal,
etc.), the figures of representative VEGF staining presented in the
relevant studies were all strongly indicative of cytoplasmic staining
being used to define positive VEGF expression in cancer cells.
All studies with one exception utilised a system of dichotomising
patients according to the percentage of positively stained cells
present. Despite the range of values used to define VEGF positivity
across the included studies, there was no evidence of any
significant association between the % cutoff value used and the
corresponding proportion of VEGF positive patients reported.
Furthermore, if including only the six studies, which used a
standardised cutoff value of 410% for meta-analysis, the
significance of the association between VEGF staining and
adverse survival was unchanged (HR¼1.62 (95% CI¼1.09–
2.40) random effects). These observations indicate that differ-
ences in the specific scoring criteria used for immunohistochem-
ical classification appear unlikely to have a significant confounding
effect in describing the underlying relationship between VEGF
expression and survival observed for the overall group.
Broadly comparable demographic and histological tumour
characteristics were observed across the eligible VEGF studies,
indicating that similar patient populations were evaluated in the
combined analysis. Data relating to adjuvant therapy was only
reported in 6 out of 11 studies and the treatment modalities
included a mix of both chemotherapy and chemoradiation.
Importantly, no studies reported any policy of selection of patients
for adjuvant therapy based on VEGF tumour expression
as immunohistochemical evaluation was undertaken on a retro-
spective basis in all cases. This was equally true for studies
evaluating the other markers of interest.
Both bcl-2 and bax emerged as potentially relevant immuno-
histochemical prognostic factors. These proteins belong to the
bcl-2 family and regulate apoptosis by mediating cytosolic release
of cytochrome C from mitochondria in response to cellular stress.
Cytochrome C binds to APAF-1 and cleaves caspase-9 into its
active form, thereby initiating the activation of executioner
caspases resulting in cytoskeletal degradation and cell death
(Hamacher et al, 2008). The bcl-2-associated X protein (bax)
promotes release of cytochrome C and consequently exhibits pro-
apoptotic properties. In contrast, bcl-2 inhibits mitochondrial
release of cytochrome C and has anti-apoptotic effects as a result.
The finding that bax expression is associated with more favourable
survival in resected pancreatic cancer is, therefore, concordant
with its physiological role. The observation that the same
relationship is consistently seen for bcl-2 expression appears
paradoxical. However, this finding is mirrored in other malig-
nancies (Martin et al, 2003; Callagy et al, 2008) and it is believed
that a complex interaction of competitive dimerisations between
pro- and anti-apoptotic proteins governs the cell’s fate in response
to apoptotic stimuli (Westphal and Kalthoff, 2003). It is difficult to
draw any reliable conclusions from the current meta-analysis of
bcl-2 and bax for the pancreatic literature due to the limited
number of evaluable studies. However, the overall trend towards
both bax and bcl-2 expression being associated with more
favourable survival outcomes is generally consistent with the
findings seen in other malignancies.
The tumour suppressor gene p16 (CDKN2A) has a key role in
pancreatic carcinogenesis (Schutte et al, 1997). p16 is a cell-cycle
checkpoint protein, which binds to cyclin-dependent kinases
resulting in cell-cycle arrest at the G1/S checkpoint.
The observation that positive immunostaining for p16 appears
to represent a favourable prognostic feature is, therefore, also
consistent with its tumour suppressor function. However, the
small number of eligible studies included in this analysis again
precludes any meaningful conclusions regarding the repro-
ducibility of p16 expression as a reliable marker of prognosis in
resected pancreatic cancer.
Of the various factors evaluated in the present study, the tumour
suppressor protein p53 was found to represent the most
extensively investigated immunohistochemical prognostic marker.
It also exhibited a significant degree of heterogeneity in the
reported association between immunostaining and survival for
individual studies. Although the overall trend was towards
overexpression of p53 resulting in adverse survival for the pooled
data, this did not reach significance and there is no obvious
explanation for the contradictory results seen between the various
studies. The majority of studies used either the monoclonal DO-7,
DO-1 or polyclonal CM-1 primary antibodies, which all exhibit
immunoreactivity with both wild-type and mutant forms of p53.
Due to the increased stability of mutant p53, most of the nuclear
immunostaining seen reflects the presence of the mutant rather
than wild-type p53 protein. Despite the marked differences
between studies in terms of the proportion of cases classified as
p53 positive, reported primary antibody dilutions used and cutoff
values selected for immunohistochemical scoring, there was no
clear association between any of these factors and either the
direction of the prognostic effect or the reported magnitude of the
HR, which might potentially explain the disparity in survival
trends. As a result of these findings, immunohistochemical
overexpression of p53 cannot be recommended as a reliable or
reproducible marker of prognosis in resected pancreatic cancer
from the available evidence.
The smad4 (or DPC4) protein is a central component of the
intracellular signalling pathway for transforming growth factor
b (TGF-b), and loss of smad4 expression represents an important
event in the progression of PanINs to invasive malignancy
(Wilentz et al, 2000). The results from the analysis of the five
studies evaluating smad4 expression again demonstrate unex-
plained heterogeneity in the reporting of the prognostic effect of
this marker. Biankin et al reported an entirely contradictory
survival trend to the other four studies with loss of smad4
expression being associated with significantly improved patient
survival despite use of the same primary antibody and otherwise
broadly comparable study methodology and patient groups. This
survival trend appears at odds with the accepted tumour
suppressor role of smad4 in mediating the inhibitory signalling
associated with the TGF-b pathway. Despite the fact that the
patient series reported by Biankin et al only accounts for 8% of all
patients included in the combined analysis and 14% of the
weighting allocated to the pooled survival data, the discrepancy in
the results is such that sufficient heterogeneity is introduced to
require a random effects approach resulting in a non-significant
result for the overall analysis. These findings further underline the
difficulties in making any reliable conclusions regarding the
relative prognostic value of immunohistochemical markers when
analysed in limited patient series.
Epidermal growth factor receptor is the cell surface receptor for
a family of extracellular ligands, which include EGF and TGF-a and
is coded for by the c-erbB1 proto-oncogene. Activation of EGFR
stimulates intracellular tyrosine kinase phosphorylation with
consequent activation of a number of signalling cascades including
the MAPK (mitogen-activated protein kinase) and Akt (protein
kinase) pathways, which promote cell proliferation (Ciardello and
Tortora, 2008). The analysis of the four eligible studies included in
the current meta-analysis again fails to make a strong case for
tumoural overexpression of EGFR representing a reproducible
prognostic marker. However, the laboratory methodologies
reported in the four studies demonstrated more marked variability
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compared with some of the other analyses.
Despite the inherent limitations of meta-analysing prognostic
literature, the findings from the present study suggest that VEGF
represents the most consistently reproducible molecular marker
with prognostic value in resected pancreatic adenocarcinoma. This
result is concordant with existing meta-analyses, which implicate a
similar prognostic role for VEGF expression in other malignancies
and lend further weight to the assertion that angiogenesis is a key
determinant in driving pancreatic cancer progression. For several
of the other markers evaluated in this study, directly contradictory
prognostic effects were commonly observed with significant
variability in the proportions of positive immunostaining reported,
despite often broadly comparable patient groups and study
methodologies. These results provide further evidence to suggest
that in order to make reliable conclusions regarding immunohis-
tochemical prognostic factors and to identify the relevance
with which these factors can be translated into clinical use (e.g.,
individualised patient selection for adjuvant therapy modalities),
large collaborative studies collecting tissue as part of prospective
multicentre trials, with standardised approaches to both laboratory
and statistical methodology, represent the optimal strategy
to achieve these goals in the future (e.g. Farrell et al, 2009;
Manuyakorn et al, 2010).
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